Expiry of Government stockpile of Molnupiravir (Lagevrio®) 200mg capsules  

Lagevrio has been deleted from Part VIIIC of the April 2025 Drug Tariff. This follows confirmation from the Department of Health and Social Care (DHSC) and Specialist Pharmacy Service that all remaining supplies of Government procured COVID-19 antiviral medicine Molnupiravir 200mg capsules (Lagevrio®) expired on 31 March 2025.

Lagevrio^® remains available for pharmacies to order directly from Alliance Healthcare, but it will now be charged at the full NHS list price. From April 2025, any pharmacy that dispenses NHS prescriptions for Lagevrio^® will be reimbursed the NHS list price as published by the manufacturer on the dictionary of medicines and devices (dm+d).

Previously, for supply against NHS prescriptions, Lagevrio^® was available to order from Alliance Healthcare without any charge with pharmacies receiving a nominal reimbursement amount of £2.50 per pack (as outlined in Part VIIIC of the Drug Tariff – Arrangements for Payment of Products Supplied Free of Charge in England). A pharmacy may request a review if they were unable to purchase Lagevrio^® without any charge in March 2025. Following a successful review, where pricing issues are identified, any adjustments will be applied by the NHS Business Service Authority (NHSBSA) to the contractors account at the earliest possible payment date.

Nirmatrelvir 150mg tablets and Ritonavir 100mg tablets (Paxlovid^®) will continue to be available to order free-of-charge from Alliance Healthcare and NHS prescriptions will be reimbursed at £2.50 per pack following Part VIIIC arrangements. 

Click here for more information on Part VIIIC arrangements.